2023 World Conference on Lung Cancer (Posters)-P1.21. DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer

P1.21. DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

Researchers have identified a potential biomarker that may help predict the efficacy of immune checkpoint inhibitors (ICIs) in the treatment of non-small-cell lung cancer (NSCLC). PD-L1 and tumor mutation burden have limited predictive value, so there is a need for alternative biomarkers to identify patients who would benefit from immunotherapy.<br /><br />The study found that patients with DOT1L mutations, which were present in 3.6% of NSCLC cases, had a better clinical response to ICI treatment. This was supported by both short-term and overall survival outcomes. The lower expression of immunosuppressive genes in DOT1L-mutated NSCLC may explain the favorable clinical outcome observed in these patients.<br /><br />The research involved a total of 393 stage III/IV NSCLC patients, including 379 patients without DOT1L mutations and 14 patients with DOT1L mutations. Three independent external cohorts with genomic, transcriptomic, and survival data were also studied to establish the clinical relevance of DOT1L mutations.<br /><br />The results suggest that baseline DOT1L mutations could be used as a predictor for the effectiveness of ICIs in NSCLC patients. This information could help in selecting the most appropriate patients for immunotherapy, potentially improving treatment outcomes and minimizing unnecessary treatments for patients who may not benefit from ICIs.<br /><br />Overall, this study provides evidence for the potential use of DOT1L mutations as a predictive biomarker for ICI efficacy in NSCLC. Further research and validation are needed to confirm these findings and to determine the clinical implications of using DOT1L mutations as a predictive marker in the selection of patients for immunotherapy.

Asset Subtitle

Yang Shao

Meta Tag

Speaker Yang Shao

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

biomarker

immune checkpoint inhibitors

non-small-cell lung cancer

NSCLC

PD-L1

tumor mutation burden

DOT1L mutations

immunotherapy

clinical response

predictive marker